|
|
||||||||
Department of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India
Reprint requests to: Tej P. Singh, Department of Biophysics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India; e-mail: tps{at}aiims.aiims.ac.in; fax: 91-11-2658 8663.
(RECEIVED September 11, 2004; FINAL REVISION October 1, 2004; ACCEPTED October 1, 2004)
| Abstract |
|---|
|
|
|---|
Keywords: n-tridecanoic acid; PLA2 complex; crystal structure; regulation
Abbreviations: PLA2, Phospholipase A2 PDB, Protein Data Bank rms, root-mean-square SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis CNS, Crystallography & NMR systems MALDITOF, matrix-assisted laser desorption/ionizationtime of flight
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.041115505.
| Introduction |
|---|
|
|
|---|
| Results and Discussion |
|---|
|
|
|---|
Sequence of PLA2
There are 411 base pairs that correspond to 137 amino acids (GenBank accession no. AY455754
[GenBank]
). The first 19 amino acids belong to a signal peptide. The mature protein has 118 amino acid residues. So far, the sequences of only four isoforms of PLA2 from Bungarus caeruleus have been determined (Fig. 1
). The sequence identities of these four isoforms varied from 73% to 85%. The present sequence has a higher pI value, and hence, it is more basic than other isomers. The most significant sequence variations are observed in the
-wing region (residues 7584) and the C-terminal part (residues 113120) of these isoforms. The notable feature of the sequences of Krait venom PLA2s is the presence of four glycines of seven residues between Cys 29 and Pro 37. It showed that the loop Cys 29Pro 37 in Krait venom PLA2s is indeed very flexible with anchors at Cys 29 and Pro 37. A strikingly notable feature in the sequence of the present PLA2 is also related to the strong presence of several basic residues such as Lys 56, Lys 83, Lys 85, Arg 88, Lys 103, and Arg 114. The corresponding residues in other isoforms of Krait PLA2 are nonbasic amino acids (Fig. 1
). Also, the presence of Leu 5 in place of conserved Phe 5 is unique to this PLA2. Only in Lys 49 group II PLA2s, such as Piratoxin II from Bothrops pirajai (Lee et al. 2001), a Lys 49 PLA2 from Agkistrodon contortrix laticinctus (PDB: 1S8G
[PDB]
; Fig. 1
), and Myotoxin I from Bothrops nummifer (de Azevedo et al. 1999), Leu is present at this position.
|
,
) (Ramachandran and Sasisekharan 1968), calculated using PROCHECK (Laskowski et al. 1993), showed that 87.6% of the residues were found in the most allowed regions.
The overall molecular framework of PLA2 conserves all main features of the PLA2 type of folding, although N-terminal helix (H1) is slightly shorter (residues 211) than that observed in earlier isoforms (Singh et al. 2001). The helix 2 (H2) extends from residues 40 to 55, while helix 3 (H3) from residues 90 to 108. The structure also contains a double-stranded antiparallel
-sheet designated as
-wing (residues 7578 and 8184). There are two helical turns involving residues 1922 (SH4) and 113115 (SH5) (Fig. 2
).
|
positions. The notable variations were observed in the calcium-binding loops and for the C-terminal segments that are generally the most flexible regions of group I PLA2s. It may be mentioned here that both of these isoforms have sodium ion in their calcium-binding loops. Also, there is a considerable change in the conformation of the segment from Trp 19 to Asn 24, as compared with earlier reported monomers (Singh et al. 2001). The side chain of Trp 19 in the present structure is significantly twisted, as compared with the earlier unliganded structure of Krait PLA2 (Singh et al. 2001). This change in the orientation of Trp 19 may be the result of complex formation with a fatty acid.
Interactions between PLA2 and n-tridecanoic acid
This is the first group I PLA2 in which a fatty acid has been observed in the hydrophobic substrate-binding site. This is also the first PLA2 with a normal catalytic composition with Asp 49, where a fatty acid has been found anchored at the substrate recognition site. The only other structures that have been observed with a fatty acid are myotoxin I from Bothrops nummifer (de Azevedo et al. 1999), piratoxin II from Bothrops pirajai (Lee et al. 2001), and a recently deposited structure of a Lys 49 PLA2 from Agkistrodon contortrix laticinctus (PDB: 1S8G
[PDB]
). All of these belong to group II and have a lysine residue at position 49. A similar electron density was also observed at the identical site in the Lys 49 PLA2 from Agkistrodon piscivorus piscivorus (Holland et al. 1990). As seen from Figure 3
, the n-tridecanoic acid is anchored to PLA2 through the most commonly observed mode of binding, in which both His 48 and Asp 49 participate. The carboxyl oxygen atom O1 of n-tridecanoic acid forms a hydrogen bond with water molecule OW7, which in turn interacts with both His 48 and Asp 49 through well-formed hydrogen bonds (Table 1
). O1 atom also forms a hydrogen bond with His 48 N
1. The second oxygen atom of the carboxyl group forms a hydrogen bond with Gly 30 N. It may be noted that in a number of PLA2-inhibitor complexes, the water molecule was found displaced by the ligand (Chandra et al. 2002a,b,c,d). In the present case, however, the binding of n-tridecanoic acid to PLA2 occurs through a water molecule that has also been observed in several PLA2-inhibitor complexes (Schevitz et al. 1995). The hydrocarbon chain of n-tridecanoic acid extends outwardly through the hydrophobic channel. The n-tridecanoic acid is almost completely buried in the hydrophobic channel of the enzyme. The buried surface areas of n-tridecanoic acid (324 Å2) and PLA2 (228 Å2) show that the two molecules are indeed in a close fit. Also, the residues that get buried in the PLA2 upon complex formation with fatty acid are Leu 5, Trp 19, Tyr 22, Gly 30, Lys 31, and Phe 101, as shown by a considerable decrease in their accessible surface areas from 76 Å2 to 22 Å2 for Trp 19; from 35 Å2 to 5 Å2 for Gly 30, and from 195 Å2 to 174 Å2 for Lys 31. It indicates that the fatty acid is inaccessible to solvent with its buried surface area amount-ing to 71% of the buried surface of PLA2. It compares well with that of palmitic acid (76%) in the myotoxin I, a Lys 49 PLA2 from Bothrops nummifer (de Azevedo et al. 1999). The solvent accessible surface areas were calculated using the CCP4 program Areaimol (Collaborative Computational Project 4 1994).
|
|
| Materials and methods |
|---|
|
|
|---|
13 kDa.
MALDITOF
The mass spectrometric analysis was performed on the washed protein crystals of krait PLA2 complex using the MALDITOF instrument (KRATOS analytical). Crystals of PLA2 were dissolved in distilled water (
10 mg/mL). Prior to the acquisition of spectra, 100 µL of PLA2 solution was mixed with 100 µL of 0.2% aqueous trifluoroacetic acid. A total of 1 µL of the acidified solution was then spotted onto a stainless-steel sample slide, followed by 1 mL of 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid) matrix solution (10 mg/mL in 50:50 ethanol/water containing 0.1% trifluoroacetic acid).
Sequence determination
The complete cDNA sequence determination of the purified samples was undertaken. The venom glands of Krait (B. caeruleus) were obtained from Irula Snake Catchers Cooperative Society, Chennai, with the permission of the Government of Tamil Nadu. The glands were collected 2 d after devenomization of the animals. The minced glands were stored in guanidine isothiocyanate (4 M) solution at 70°C prior to use. The tissues were homogenized using polytron (Kinematica) homogenizer. The total RNA was extracted with an equal volume of phenolchloroform (1:1) mixture. Quantification of RNA was done spectrophotometrically. A total of 10 µg of total RNA was used for cDNA synthesis using Revert Aid M-MuLV reverse transcriptase (MBI) and oligo (dT)18 primer. Conserved nucleotide sequences of group I PLA2s were used for construction of primers. The oligonucleotides 5'-AAATGTATC CTGCTCACCTTCT-3' and 5'-GCTGAAGCCTCTCAAATATC AT-3' were used as forward and reverse primers, respectively, in PCR amplification using PTC 100 thermocycler (MJ Research). Automated DNA sequencing of the PCR product was performed in ABI-377 sequencer. Both of the strands were sequenced. The sequence was submitted to GenBank (GenBank accession no. AY455754
[GenBank]
).
Crystallization of the PLA2 n-tridecanoic acid complex
The crystals of the PLA2-TDA complex were obtained by the sitting-drop vapor-diffusion method. The protein was dissolved at 20 mg/mL in 50 mM Tris-HCl buffer (pH 8.5) containing 1.4 M NaCl, 1 mM NaN3. It was equilibrated with the same buffer containing 2.4 M NaCl. After 3 d, the crystals were found to have grown to the largest size of 0.3 x 0.2 x 0.2 mm3.
Data collection and processing
The crystals of the complex were mounted in glass capillaries. X-ray intensities were measured at 285 K using a 345-mm MAR Research imaging plate scanner mounted on a Rigaku RU-300 X-ray generator equipped with focusing mirrors. The data were processed and scaled using DENZO and SCALEPACK (Otwinowski and Minor 1997). The crystals belong to space group P41212 with unit cell dimensions of a = b = 53.8 Å, c = 82.5 Å. The details of data collection statistics are summarized in Table 2
.
|
200 reflections), which were randomly selected for the free R calculations (Brünger 1992), and the other set consisting of the rest of the data (3200 reflections). During the refinement, the bond lengths and bond angles were restrained close to the standard values, and restraints were also placed on the planarity of groups and nonbonded contacts as defined by Engh and Huber (1991). Several cycles of refinement using rigid-body conjugate-gradient minimization, simulated-annealing, and model building with the program O (Jones et al. 1991), brought the R-factor down to 0.30 and the R-free to 0.415 for all of the data in the resolution range 20.02.7 Å. At this stage, the individual isotropic B-factor refinement was carried out, which reduced the R-factor to 0.260 and R-free to 0.334. Manual model building using |2FoFc| and |FoFc| electron density maps and further refinement by simulated annealing with molecular dynamics using a slow-cooling protocol from 3000 to 300 K (Brünger et al. 1990), brought the R-factor down to 0.234 and R-free to 0.321 for the reflections in the resolution range 20.02.7 Å. An extra nonprotein electron density was observed at the hydrophobic substrate-binding channel of PLA2 at about 3.0
cut off in the |FoFc| map into which a molecule of fatty acid, n-tridecanoic acid, was readily fitted (Fig. 3
cut off. Together with these, the positions of 60 water molecules were also determined in the model for which the peaks were >2.5
in the |FoFc| map, were at appropriate distances from the hydrogen-bond partners, and B values were <50 Å2 after refinement. The refinement improved further and finally converged to R and R-free factors of 0.198 and 0.241, respectively. The final refinement statistics for the structure are listed in Table 3
|
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
Brünger, A.T., Krukowski, A., and Erickson, J. 1990. Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta Crystallogr. A 46: 585593.
Brünger, A.T., Adams, P.D., Clore, G.M., Delano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, N., Pannu, N.S., et al. 1998. Crystallography and NMR system (CNS) A new software system for macromolecular structure determination. Acta Crystallogr. D 54: 905921.[CrossRef][Medline]
Cha, S.S., Lee, D., Adams, J., Kurdyla, J.T., Jones, C.S., Marshall, L.A., Bolognese, B., Abdel-Meguid, S.S., and Oh, B.H. 1996. High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX). J. Med. Chem. 39: 38783881.[CrossRef][Medline]
Chandra, V., Jasti, J., Kaur, P., Srinivasan, A., Betzel, Ch., and Singh, T.P. 2002a. Structural basis of phospholipase A2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7 Å crystal structure. Biochemistry 41: 1091410919.[CrossRef][Medline]
Chandra, V., Jasti, J., Kaur, P., Betzel, Ch., Srinivasan, A., and Singh, T.P. 2002b. First structural evidence of a specific inhibition of phospholipase A2 by
-tocopherol (vitamin E) and its implications in inflammation: Crystal structure of the complex formed between phospholipase A2 and
-tocopherol at 1.8 Å resolution. J. Mol. Biol. 320: 215222.[CrossRef][Medline]
Chandra, V., Jasti, J., Kaur, P., Dey, S., Perbandt, M., Srinivasan, A., Betzel, Ch., and Singh, T.P. 2002c. Crystal structure of a complex formed between a snake venom phospholipase A2 and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å resolution. J. Biol. Chem. 277: 4107941085.
Chandra, V., Jasti, J., Kaur, P., Dey, S., Srinivasan, A., Betzel, Ch., and Singh, T.P. 2002d. Design of specific peptide inhibitors of phospholipase A2: Structure of a complex formed between Russells viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). Acta Crystallogr. D 58: 18131819.[CrossRef][Medline]
Collaborative Computational Project 4. 1994. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D 50: 760763.[CrossRef][Medline]
Davidson, F.F. and Dennis, E.A. 1990. Evolutionary relationships and implications for the regulation of phospholipase A2: From snake venom to human secreted forms. J. Mol. Evol. 31: 228238.[CrossRef][Medline]
de Azevedo Jr., W.F., Ward, R.J., Gutierrez, J.M., and Arni, R.K. 1999. Structure of a Lys49-phospholipase A2 homologue isolated from the venom of Bothrops nummifer (jumping viper). Toxicon 37: 371384.[Medline]
Dennis, E.A. 1987. The Regulation of eicosanoid production: Role of phospholipases and inhibitors. BioTechnoloy 5: 12941300. (Reprinted in 1989. Biochimica Clinica 13: 215223).[CrossRef]
Dodson, E.J., Winn, M., and Ralph, A. 1997. Collaborative Computational Project 4: Providing programs for protein crystallography. Methods Enzymol. 277: 620633.[Medline]
Engh, R.A. and Huber, R. 1991. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr. A 47: 392400.[CrossRef]
Esnouf, R.M. 1997. An extensively modified version of Molscript that includes greatly enhanced coloring capabilities. J. Mol. Graphics 15: 132134.[CrossRef][Medline]
Georgieva, D.N., Rypniewski, W., Gabdoulkhakov, A., Genov, N., and Betzel, C. 2004. Asp49 phospholipase A(2)-elaidoylamide complex: A new mode of inhibition. Biochem. Biophys. Res. Commun. 319: 13141321.[CrossRef][Medline]
Hansford, K.A., Reid, R.C., Clark, C.I., Tyndall, J.D., Whitehouse, M.W., Guthrie, T., McGeary, R.P., Schafer, K., Martin, J.L., and Fairlie, D.P. 2003. D-Tyrosine as a chiral precusor to potent inhibitors of human non-pancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 4: 181185.[CrossRef][Medline]
Heinrikson, R.L., Kruenger, E.T., and Keim, P.S. 1977. Amino acid sequence of phospholipase A2-
from the venom of Crotalus adamanteus. A new classification of phospholipases A2 based upon structural determinants. J. Biol. Chem. 252: 49134921.
Holland, D.R., Clancy, L.L., Muchmore, S.W., Ryde, T.J., Einspahr, H.M., Finzel, B.C., Heinrikson, RL., and Watenpaugh, K.D. 1990. The crystal structure of a lysine 49 phospholipase A2 from the venom of the cottonmouth snake at 2.0 Å resolution. J. Biol. Chem. 265: 1764917656.
Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. 1991. Improved methods for building models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110119.
Kraulis, P.J. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24: 946950.[CrossRef]
Laskowski, R., Macarthur, M., Moss, D., and Thornton, J. 1993. Procheck: A program to check stereochemical quality of protein structures. J. Appl. Crystallogr. 26: 283290.[CrossRef]
Lee, W.H., da Silva Giotto, M.T., Marangoni, S., Toyama, M.H., Polikarpov, I., and Garratt, R.C. 2001. Structural basis for low catalytic activity in Lys49 phospholipases A2-a hypothesis: The crystal structure of piratoxin II complexed to fatty acid. Biochemistry 40: 2836.[CrossRef][Medline]
Merritt, E.A. Raster 3D version 2.0: A program for photorealistic molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 50: 869873.
Navaza, J. 1994. AmoRe: An automated package for molecular replacement. Acta Crystallogr. A 50: 157163.[CrossRef]
Otwinowski, Z. and Minor, W. 1997. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307326.
Ramachandran, G.N. and Sasisekharan, V. 1968. Conformation of polypeptides and proteins. Adv. Protein Chem. 23: 283438.[Medline]
Schevitz, R.W., Bach, N.J., Carlson, D.G., Chirgadze, N.Y., Clawson, D.K., Dillard, R.D., Draheim, S.E., Hartley, L.W., Jones, N.D., and Mihelich, E.D. 1995. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat. Struct. Biol. 2: 458465.[CrossRef][Medline]
Scott, D.L., Otwinowski, Z., Gelb, M.H., and Sigler, P.B. 1990. Crystal structure of beevenom phospholipase A2 in a complex with a transition-state analogue. Science 250: 15631566.
Scott, D.L., White, S.P., Browning, J.L., Rosa, J.J., Gelb, M.H., and Sigler, P.B. 1991. Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudates. Science 254: 10071010.
Sekar, K., Eswaramoorthy, S., Jain, M.K., and Sundaralingam, M. 1997. Crystal structure of the complex of bovine pancreatic phospholipase A2 with the inhibitor 1-hexadecyl-3-(trifluoroethyl)-sn-glycerol-2-phosphomethanol. Biochemistry 36: 1418614191.[CrossRef][Medline]
Sekar, K., Kumar, A., Liu, X., Tsai, M.D., Gelb, M.H., and Sundaralingam, M. 1998. Structure of the complex of bovine pancreatic phospholipase A2 with a transition-state analogue. Acta Cryst. D 54: 334341.[CrossRef][Medline]
Singh, G., Gourinath, S., Sharma, S., Paramasivam, M., Srinivasan, A., and Singh, T.P. 2001. Sequence and crystal structure determination of a basic phospholipase A2 from common krait (bungarus caeruleus) at 2.4 Å resolution: Identification and characterization of its pharmacological sites. J. Mol. Biol. 307: 10491059.[CrossRef][Medline]
Singh, R.K., Vikram, P., Makker, J., Jabeen, T., Sharma, S., Dey, S., Kaur, P., Srinivasan, A., and Singh T.P. 2003. Design of specific peptide inhibitors for group I phospholipase A2: Structure of a complex formed between phospholipase A2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 Å resolution reveals unique features. Biochemistry 40: 1170111706.[CrossRef]
Thunnissen, M.M., Ab, E., Kalk, K.H., Drenth, J., Dijkstra, B.W., Kuipers, O.P., Dijkman, R., de Haas, G.H., and Verheij, H.M. 1990. X-ray structure of phospholipase A2 complexed with a substrate-derived inhibitor. Nature 347: 689691.[CrossRef][Medline]
van Deenen, L.L.M. and de Haas, G.H. 1963. The substrate specificity of phospholipase A2. Biochem. Biophys. Acta. 70: 538553.
Verheij, H.M., Volwerk, J.J., Jansen, E.H., Puijk, W.C., Dijkstra, B.W., Drenth, J., and de Haas, G.H. 1980. Methylation of histidine-48 in pancreatic phospholipase A2. Role of histidine and calcium ion in the catalytic mechanism. Biochemistry 19: 743750.[CrossRef][Medline]
White, S.P., Scott, D.L., Otwinowski, Z., Gelb, M.H., and Sigler, P.B. 1990. Crystal structure of cobravenom phospholipase A2 in a complex with a transition-state analogue. Science 250: 15601563.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |